About Genoskin
Advancing human-relevant research with real human skin models
At Genoskin, we bridge the gap between lab research & human biology
We deliver human-relevant data that de-risks R&D pipelines and reduces reliance on animal testing


Mission, vision & values
As only 10% of drug development projects actually make it to the market, we decided to place our expertise in skin biology and immunology at the core of our approach.


We partner with pharmaceutical and biotech companies to accelerate drug development, ensuring patients receive faster access to new treatments. We extend this expertise to consumer goods and cosmetics companies, helping them bring trusted, high-quality products to market. Genoskin couples its unique human skin platforms with hi-tech tools and artificial intelligence. We increasingly focus on immunocompetent human skin that yields human data to help drug and product development projects move forward.


Mission
Enable safer, and more ethical therapeutic & product development with human-relevant models.


Vision
A future where medical innovation no longer solely relies on animal testing, but on predictive human-based data.


Values
Innovation
Collaboration
Human relevance.
Genoskin history




Our expertise




Scientific expertise
Ex vivo human skin platforms combined with extensive immunology expertise and recognized by peer-reviewed research and publications.


What we deliver
Supporting drug developers, cosmetic innovators, and medical device manufacturers with local toxicity, vaccine research, topical delivery, and safety testing.


Global reach
Operations in France and the US, serving customers and partners around the world.


Proven impact
+90 scientific publications citing Genoskin technology, collaborations with leading academic and industry experts, and recognition as a European growth leader.
Our executive team




Pascal Descargues, PhD
Founder, CEO
About our CEO & Founder
Back in 2009, as a researcher in skin biology and rare skin diseases, Pascal realized that animals are not replicating human biology effectively enough. He also realized that thousands of human skin samples discarded from plastic surgeries every year, could be used to help researchers to discover new drugs and avoid animal experimentation.
Pascal saw the opportunity to use an abundantly available resource without having to harm animals and without having to support all the costs associated with animal experimentation. Discarded human skin samples are precious, because they’re human, more reliable and can help researchers to reduce development cost and time to get drugs to market by offering access to reliable human data.


Frederick Roques
Chief Financial Officer
Meet our Chief Financial Officer
With his multi-sector and multi-standard (PCG, IFRS, US GAAP) experience, he continues to structure, transform and optimize the financial aspects of Genoskin. Also taking an active part in the general administration, Frederick structures the back office to leverage the continual growth of Genoskin through modern tools and process optimization.
Frederick holds a Masters in Finance, Accounting and Business Administration from the University of Toulouse and is a licensed French Accountant and External Auditor.


Nicolas Gaudenzio, PhD
Chief Scientific Officer
Meet our Chief Scientific Officer
Dr Gaudenzio’s work has been published in prestigious scientific journals such as Nature Immunology, Nature Medicine, Cell, Science, Nature Communications and others. He is a member of the European Academy of Allergy and Clinical Immunology (EAACI) and the French Society for Immunology (SFI).


Anna Falkovsky
Vice President of Sales
Meet our Vice President of Sales


Lorna Santos, PhD
Vice President of Research & Product Development
Meet our VP of Research & Product Development
Transitioning from academia to the commercial sector, Lorna began her career as a Product Manager at prominent biotechnology and preclinical CRO companies, including Cell Signaling Technology, Abcam, and Charles River Labs. She then advanced to director-level positions, where she successfully led and grew global teams at Crown Bioscience and Akoya Bioscience.
In July 2023, Lorna joined the Genoskin team as the VP of Research & Product Development, bringing with her over 15 years of expertise in research, product development, marketing, and product management.


Nicolas Fourrier, PhD
Vice President of Scientific Operations
Meet our Vice President of Scientific Operations
He began his industry career at The Binding Site Group in the United Kingdom, where he progressed from protein purification scientist to team leader in immunoassay development and validation. In 2012, he joined SGS France, subsequently becoming Director of the Biomarker and Biopharmaceutical Testing Group, overseeing bioanalytical activities supporting biotherapeutic drug development. He joined Inotrem in 2021 as Director of Clinical Biomarkers, Translational Research and Biologistics.
At Genoskin, Nicolas brings together scientific expertise and experience leading laboratory teams, with a strong background in developing and validating assays to support the evaluation of biological therapies.


Stéphanie Delluc, PhD
Vice President of Lab Production
Meet our Vice President of Lab Production
Today, Stéphanie leads Genoskin’s Salem, Massachusetts site while driving our global production strategy across the US and France. Her mission goes far beyond increasing production capacity. It is about making sure that, as Genoskin grows, we preserve what matters most: scientific rigor, quality, reproducibility, and the human relevance of our models.
With a PhD in Immunology and experience leading multidisciplinary teams across biotech, pharma, and CRO environments, Stéphanie brings both a scientific and operational perspective to Genoskin’s next stage of growth.







